End Stage Renal Disease (ESRD) Drug Market Set To Expand From $304.06 Billion In 2026: Growth Outlook Through 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
End Stage Renal Disease (ESRD) Drug Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The market size for end stage renal disease (esrd) drugs has expanded quickly in recent years. It is forecast to increase from $148.55 billion in 2025 to $171.12 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.2%. The historical growth can be linked to the rising prevalence of ckd, heightened awareness of esrd, an increase in dialysis centers, breakthroughs in renal therapeutics, and government healthcare initiatives.
The end stage renal disease (esrd) drug market is anticipated to undergo significant expansion in the upcoming years. It is forecast to reach $304.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.5%. This growth in the forecast period stems from the progress in precision medicine, the increased availability of homecare dialysis, the incorporation of AI into patient monitoring, heightened investments in esrd research and development, and the rising use of combination therapies. Notable trends for this period include tailored esrd drug therapy, home-based dialysis solutions, the integration of telemedicine in ckd management, advanced drug formulations for addressing secondary complications, and a growing adoption of combination therapies.
Get A Free Sample Report With In-Depth Market Insights:
End Stage Renal Disease (ESRD) Drug Market Growth Backed By Core Demand Fundamentals
The growing prevalence of obesity and diabetes is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity is characterized by an excessive or unhealthy accumulation of body fat, presenting significant health risks. Conversely, diabetes refers to a long-term condition where the pancreas either fails to produce adequate insulin or the body struggles to effectively use the insulin it produces. For individuals suffering from renal disease, interventions like dialysis that manage fluid and electrolyte balance, blood pressure, and waste removal can enhance overall health, potentially leading to weight loss and better regulation of blood sugar. To illustrate this, in 2023, the World Obesity Federation, a non-profit membership organization, estimated that by 2035, the yearly economic burden of overweight and obesity will hit US$ 4.32 trillion, which is roughly 3% of global GDP. Additionally, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, representing an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the increasing incidence of obesity and diabetes will stimulate the market for end-stage renal disease (ESRD) drugs.
End Stage Renal Disease (ESRD) Drug Market Segment Landscape: Which Areas Lead Development?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
End Stage Renal Disease (ESRD) Drug Market Growth Trends Reshaping The Competitive Landscape
Leading companies active in the end-stage renal disease (ESRD) drug market are concentrating on product approvals, such as for Jardiance, to boost their revenues within this sector. Empagliflozin is a medication formulated to assist individuals with type 2 diabetes and to reduce the likelihood of cardiovascular complications in those with type 2 diabetes who also have heart failure or cardiovascular disease. For example, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, secured FDA approval for Jardiance. Jardiance has been sanctioned for various indications, including lowering the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease who are at risk of progression, as well as reducing the risk of a sustained decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor and is contraindicated in patients diagnosed with type 1 diabetes and those exhibiting an eGFR less than 20 ml/min/1.73 m.
End Stage Renal Disease (ESRD) Drug Market Industry Leaders And Competitive Landscape
Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
View The Full End Stage Renal Disease (ESRD) Drug Market Report:
End Stage Renal Disease (ESRD) Drug Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
